Ocumension Therapeutics (HK:1477)
:1477
Top Page
Ocumension Therapeutics
(1477)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$7.00
▼(-7.28% Downside)
Action:ReiteratedDate:11/01/25
Ocumension Therapeutics faces significant profitability and cash flow challenges despite strong revenue growth. The technical analysis suggests mixed momentum, and the valuation indicates potential overvaluation. These factors contribute to a cautious outlook.
Positive Factors
High Revenue Growth
Sustained top-line growth near +70% demonstrates strong market adoption of Ocumension's ophthalmic products and expanding commercial traction. Durable revenue expansion supports scale economics, funds continued R&D investment, and improves the company's ability to leverage fixed costs over the medium term.
Negative Factors
Sustained Net Losses
Deep negative operating and net margins reflect that current revenues do not cover operating and development costs. Persistent losses erode retained capital, limit internal funding for growth, and increase reliance on external financing until the company can achieve sustainable positive margins.
Read all positive and negative factors
Positive Factors
Negative Factors
High Revenue Growth
Sustained top-line growth near +70% demonstrates strong market adoption of Ocumension's ophthalmic products and expanding commercial traction. Durable revenue expansion supports scale economics, funds continued R&D investment, and improves the company's ability to leverage fixed costs over the medium term.
Read all positive factors
Ocumension Therapeutics (1477) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.78B
Dividend YieldN/A
Average Volume (3M)3.41M
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth74.73%
EPS Growth32.13%
CountryHK
Employees489
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding836,331,900
10 Day Avg. Volume1,456,522
30 Day Avg. Volume3,406,832
Financial Highlights & Ratios
PEG Ratio0.32
Price to Book (P/B)0.77
Price to Sales (P/S)6.97
P/FCF Ratio-7.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.16Price Target Upside34.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.01
Revenue Forecast (FY)HK$1.10B
Ocumension Therapeutics Business Overview & Revenue Model
Company Description
Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers ...
How the Company Makes Money
Ocumension Therapeutics generates revenue through a multi-faceted business model that includes the development and sale of its proprietary drug products, licensing agreements, and partnerships with other pharmaceutical companies. The company's key...
Ocumension Therapeutics Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 543.72M | 417.31M | 246.37M | 158.96M | 56.15M | 13.10M |
| Gross Profit | 231.51M | 225.06M | 144.37M | 102.92M | 36.94M | 11.37M |
| EBITDA | -198.88M | -188.03M | -320.62M | -359.98M | -249.81M | -2.26B |
| Net Income | -249.25M | -268.27M | -379.79M | -402.64M | -259.99M | -2.26B |
Balance Sheet | ||||||
| Total Assets | 3.90B | 3.97B | 3.27B | 3.04B | 3.33B | 2.60B |
| Cash, Cash Equivalents and Short-Term Investments | 578.27M | 769.21M | 1.05B | 1.29B | 1.77B | 2.03B |
| Total Debt | 83.22M | 25.78M | 137.98M | 29.58M | 11.21M | 7.24M |
| Total Liabilities | 243.82M | 200.19M | 351.03M | 295.04M | 222.88M | 97.23M |
| Stockholders Equity | 3.65B | 3.77B | 2.92B | 2.75B | 3.11B | 2.50B |
Cash Flow | ||||||
| Free Cash Flow | -195.07M | -408.97M | -539.79M | -510.66M | -861.66M | -517.18M |
| Operating Cash Flow | -160.92M | -178.83M | -177.93M | -200.66M | -196.85M | -212.57M |
| Investing Cash Flow | -174.67M | 275.91M | -259.78M | 229.15M | -1.35B | 629.70M |
| Financing Cash Flow | -69.99M | -213.79M | 108.66M | -9.22M | 668.85M | 1.53B |
Ocumension Therapeutics Technical Analysis
Positive
7.55
Price Trends
7.15
Positive
7.59
Positive
8.51
Negative
Market Momentum
0.27
Negative
66.32
Neutral
86.05
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Positive. The current price of 7.55 is above the 20-day moving average (MA) of 7.23, above the 50-day MA of 7.15, and below the 200-day MA of 8.51, indicating a neutral trend. The MACD of 0.27 indicates Negative momentum. The RSI at 66.32 is Neutral, neither overbought nor oversold. The STOCH value of 86.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1477.
Ocumension Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$6.78B | -34.12 | -4.32% | ― | 74.73% | 32.13% | |
47 Neutral | HK$1.70B | -7.14 | -12.64% | ― | -38.38% | -22.12% | |
44 Neutral | HK$7.21B | -41.82 | -5.07% | ― | 2.10% | -1350.00% | |
42 Neutral | HK$13.88B | -15.44 | -64.19% | ― | -55.64% | -158.67% | |
40 Underperform | HK$11.08B | 30.77 | 24.17% | ― | 240.05% | -140.09% |
* Healthcare Sector Average
HK:1477
Ocumension Therapeutics
8.32
4.07
95.76%
HK:2157
Lepu Biopharma Co. Ltd. Class H
5.96
2.59
76.85%
HK:2616
CStone Pharmaceuticals
9.55
7.33
330.18%
HK:6622
Zhaoke Ophthalmology Ltd.
3.09
1.70
122.30%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
7.50
-0.70
-8.54%
HK:0775
CK Life Sciences International (Holdings), Inc.
0.75
0.27
56.25%
Ocumension Therapeutics Corporate Events
Ocumension Completes Patient Enrollment for Real-World Study of OT-703 in Hainan
Jan 19, 2026
Ocumension Therapeutics has completed enrollment of 195 patients in a real-world study of OT-703 (ILUVIEN), a fluocinolone acetonide intravitreal implant for diabetic macular edema, at the Boao Lecheng International Medical Tourism Pilot Zone in H...
Ocumension Increases Treasury Share Holdings to Nearly 21 Million
Dec 19, 2025
Ocumension Therapeutics has updated investors on its share repurchase activity, disclosing that the number of shares bought back and held in treasury has increased from 17,086,000 as of 31 December 2024 to 20,949,500 as of 19 December 2025. The co...
Ocumension Therapeutics Gains Approval for OT-702 in China
Nov 26, 2025
Ocumension Therapeutics announced that its biosimilar product OT-702, developed in collaboration with Shandong Boan Biotechnology, has received marketing approval from China’s National Medical Products Administration for treating neovascular...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.